Choosing a country will allow you to access local content and enable you to shop in your local currency.
During the past few decades, breakthroughs in cell and molecular biology have allowed significant advances in science and medicine. Modern cell-based products are often genetically engineered, such as immune cells for immunotherapies or stem cells for regenerative medicine.
GE Healthcare has a steadily growing range of innovative solutions that you can utilize to grow the future of cell therapy, such as bioreactors and cell culture reagents for cell expansion and powerful tools for cellular imaging and analysis. Follow the product links on the bottom of the page or go to Cell Preparation, Expansion, and Analysis.
Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress an immune response are classified as suppression immunotherapies. Suppression therapies are used to control autoimmune diseases or allergies, while activation immunotherapies are being developed to stimulate immune responses against diseases such as cancer.
Immune effector cells (e.g., lymphocytes, macrophages, dendritic cells, natural killer [NK] cells, and cytotoxic T lymphocytes [CTL]) work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumors. Two major strategies are employed in cancer immunotherapy, so-called active immunotherapy and passive immunotherapy.
Active immunotherapy is intended to activate the immune system of the patient in order to mount a specific immune response able to recognize and destroy the tumor. Dendritic cells have a central role in stimulating immune responses by presenting antigens to immune effector cells. In some experimental immunotherapies, dendritic cells are either pulsed with tumor antigens (protein or peptides) or transfected with a viral vector expressing tumor antigen. If injected into a cancer patient, the modified dendritic cells could present tumor antigen in vivo, activating tumor-specific effector cells to mount an antitumor immune response.
Passive immunotherapy also uses dendritic cells, but instead of in vivo stimulation, immune effector cells (i.e., T lymphocytes) are activated in vitro and then transferred back into the patient where they recognize and destroy tumor cells. Autologous tumor-infiltrating lymphocytes (TILs), for example, have been successfully applied to treat patients with metastatic melanoma, by priming T cells extracted from the tumor milieu. TILs proliferate in vitro by exposure to high concentrations of IL-2, anti-CD3, and allo-reactive feeder cells.
Donated organs and tissues are often used to replace damaged tissue, but demand far outweighs the available supply. Stem cells, directed to differentiate into specific cell types, may provide a renewable source of replacement cells and tissues to treat a wide range of diseases, from Alzheimer's disease to rheumatoid arthritis.
Adult stem cell treatments have been successfully used for many years in bone marrow transplants to treat leukemia and related bone/blood cancers. Alternatively, umbilical cord blood stem cells can be used in hematopoietic stem cell transplants for patients lacking a matched donor.
Although tissue engineering is still in its infancy, this modern approach to cell transplantation has recently progressed as organs and tissues are now being grown in the lab from stem cells and transplanted into patients. In cell replacement therapy, stem cells are differentiated into cells of the target organ or tissue for later injection into the organ or tissue that needs repair. For instance, stem cells may be used in the future to replace damaged brain tissue in Alzheimer’s patients.
In some cases the transplanted cells must attach and replace damaged tissue, while in other cases the infused cells are only meant to release certain factors such as enzymes or growth factors. For example, in the case of insulin-secreting islets for the treatment of diabetes.
WAVE Bioreactor systems together with Cellbag Bioreactors provide a closed, cost-efficient system for culture and expansion of a wide range of cells, suitable for cGMP-compliant environments.
IN Cell Analyzer systems are designed to deliver the throughput and performance you need for both high-content analysis (HCA) and high-content screening (HCS) of fixed and live cells.
This outsourcing service increases the capability and capacity of researchers who use cell based assays for high throughput and high content screening.
Detect low abundant secreted proteins or membrane surface markers using our range of immunoassays.
We've detected that you're using an unsupported browser.You may continue browsing, but for the best experience, please use Mozilla Firefox (v.30+), Google Chrome (v.35+) or Internet Explorer (v.11+).